# Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)

> **NCT02758587** · PHASE1,PHASE2 · UNKNOWN · sponsor: **NHS Greater Glasgow and Clyde** · enrollment: 59 (estimated)

## Conditions studied

- Carcinoma, Non-small-cell Lung
- Mesothelioma
- Pancreatic Neoplasms

## Interventions

- **DRUG:** Defactinib
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT02758587
- **Lead sponsor:** NHS Greater Glasgow and Clyde
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-07-04
- **Primary completion:** 2019-05
- **Final completion:** 2021-12
- **Target enrollment:** 59 (ESTIMATED)
- **Last updated:** 2018-03-19

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02758587

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02758587, "Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02758587. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*